SSTR5 antagonist 2 TFA

Cat. No.:	HY-114191A
CAS No.:	1254733-98-6
Molecular Formula:	$C_{34}H_{36}F_4N_2O_7$
Molecular Weight:	660.65
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and **selective somatostatin (receptor) subtype 5 (SSTR5)** antagonist and has potential to treat type 2 diabetes mellitus (T2DM)[1].
IC_{50} & Target	SSTR5[1].
In Vivo	SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1]. SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1].

Animal Model:	Rodent diabetic model without risk of hypoglycemia[1].
Dosage:	10 mg/kg.
Administration:	Orally.
Result:	Increased both total and active circulating incretin hormone GLP1 levels.

REFERENCES

[1]. Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA